Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

ACQUISITIONS - Narratives (Details) - USD ($) $ / shares in Units, $ in Millions	Apr. 18, 2019	Feb. 11, 2019	Dec. 01, 2017	Jul. 03, 2015
CAS Medical Systems, Inc.
Business Acquisition [Line Items]
Consideration per share to be transferred (in dollars per share)		$ 2.45
Acquisition price, subject uncertain adjustments		$ 100.0
Cash purchase price	$ 100.2
Harpoon Medical
Business Acquisition [Line Items]
Additional research and development expenditures to be incurred prior to product introduction			$ 41.4
CardiAQ
Business Acquisition [Line Items]
Additional research and development expenditures to be incurred prior to product introduction				$ 97.7